Experimental Drug Shows Promise as Possible Coronavirus Treatment

Headline Roundup April 29th, 2020

Remdisivir, an experimental anti-viral drug, has reportedly generated "positive" data in tests run by the National Institute of Allergy and Infectious Diseases (NIAID) to examine its potential as a COVID-19 coronavirus treatment. Dr. Anthony Fauci and President Donald Trump were among those who celebrated the "good news" Wednesday; the Food and Drug Administration (FDA) is discussing plans with Gilead Sciences, remdisivir's developer, to make the drug publicly available pending an emergency use authorization.

Reporting from throughout the spectrum focused on top officials' reserved optimism regarding the test results, specific details of the experiments and how the drug purportedly works, and an ensuing uptick for the stock market.

From the Center
344

President Donald Trump said Wednesday that he wants the Food and Drug Administration to move “as quickly as they can” to approve Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus.

“We would like to see very quick approvals, especially with things that work,” he said at a roundtable at the White House with business executives Wednesday evening.

Earlier in the day, the FDA said it has been in “sustained and ongoing” discussions with Gilead to make remdesivir available to Covid-19 patients “as quickly as possible, as appropriate.”...

Read full story
Some content from this outlet may be limited or behind a paywall.
From the Right
344

The experimental coronavirus treatment remdesivir has generated “positive data” in a trial of the antiviral organized by the National Institute of Allergy and Infectious Diseases (NIAID), according to developer Gilead Sciences.

“We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing,” said Gilead in a statement released Wednesday.

The NIAID study is a double-blind placebo-controlled trial encompassing more than 800 patients, according to a recent document posted by Gilead on its website. The study involves patients with critical, severe...

Read full story
From the Left
344

An experimental antiviral drug to treat COVID-19 patients has fanned high expectations in the fight against the coronavirus pandemic, which has gained a decisive foothold in the United States and continues to spread around the world.

Gilead Sciences (GILD) acknowledged Wednesday that its drug, remdisivir, has seen positive results in both a company-sponsored and National Institute of Health-run study — with the federal regulators reportedly prepared to bestow emergency approval on the drug, according to The New York Times.

The treatment has been a frontrunner in the treatment race for...

Read full story

Discuss & Debate

Want to help speed up problem solving in America? This Monday, September 20th, Americans from across the political spectrum will meet in small groups to discuss how they think our representatives should approach infrastructure. The results of these conversations will be shared with Congress.

Learn about America Talks Infrastructure